Ethnic differences in the treatment and control of hypertension in patients with diabetes.
Ethnic differences in the treatment and control of hypertension in patients with diabetes.
复制标题
糖尿病患者高血压治疗和控制的种族差异。
DOI：
10.1111/j.1524-6175.2005.04542.x
复制
发表时间：
2005
期刊：
影响因子：
--
通讯作者：
Egan,BrentM
中科院分区：
文献类型：
--
作者：
Riehle,JessicaFlynn;Lackland,DanielT;Okonofua,EniC;Hendrix,KatherineH;Egan,BrentM
Among diabetic hypertensive patients, ethnic differences in blood pressure control and outcomes have been attributed in part to greater reluctance of providers to prescribe combination antihypertensive regimens to African Americans than to Caucasians. African Americans purportedly receive fewer angiotensin‐converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs), which reduce target organ complications. To assess these issues, cross‐sectional data were analyzed from 19,864 diabetic hypertensives from 62 primary care clinics. Among diabetic hypertensives, African Americans (N=6230) were less likely than Caucasians (N=8041) to have blood pressure (BP) ≤130/80 mm Hg at their last clinic visit (23.1% [23.0%–23.2%] vs. 30.7% [30.6%–30.9%]) despite a greater number of prescriptions for antihypertensive medications (2.67 [2.63‐2.70] vs. 2.23 [2.20‐2.26]). African Americans were more likely than Caucasians to have an ACEI and/or ARB prescribed and to receive prescriptions for at least two antihypertensive medications that included an ACEI or ARB (64.1 % [63.8%–64.4%] vs. 53.1% [52.8%–53.4%]). Among diabetic hypertensives, African Americans are less likely than Caucasians to attain BP <130/80 mm Hg, despite receiving more antihypertensive medication prescriptions. African Americans receive more ACEIs and/or ARBs than Caucasians for target organ protection and/or BP control. The data suggest provider prescribing patterns are not a major contributor to ethnic differences in BP control and outcomes in diabetic hypertensives.
登录
查看更多内容
血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂治疗糖尿病肾病的回顾性比较
影响因子：
2.9
作者：
N. Robles;B. Romero;E. Fernandez;E. Sánchez;J. Cubero
通讯作者：
J. Cubero
DOI：
--
发表时间：
2006
期刊：
Nature Clinical Practice Nephrology
影响因子：
--
作者：
E. Ritz;R. Dikow
通讯作者：
R. Dikow
厄贝沙坦对动态血压和诊室血压的比较影响：2 型糖尿病和微量白蛋白尿患者中厄贝沙坦动态血压的子研究。
影响因子：
16.2
作者：
K. Rossing;P. Christensen;S. Andersen;P. Hovind;H. Hansen;H. Parving
通讯作者：
H. Parving
影响因子：
39.2
作者：
RAVID, M;SAVIN, H;LISHNER, M
通讯作者：
LISHNER, M
治疗糖尿病肾病高血压。
影响因子：
16.2
作者：
J. Tomlinson;K. Owen;C. Close
通讯作者：
C. Close